Description: Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.Palazestrant inhibits 17b-estradiol (E2), inhibits MCF7 and CAMA-1 cell proliferation, and can be used in breast cancer research. Target: Estrogen Receptor/ERR,...

An ERalpha antagonist (IC50 = 6.4 nM), induces degradation of ERalpha in MCF-7 cells (EC50 = 0.52 nM), decreases the proliferation of MCF-7 and CAMA-1 breast cancer cells (IC50s = 1.8 and 1.7 nM, respectively), inhibits estradiol-induced cell cycle progression in the same cells at 100 nM, reduces tumor growth and...